In this briefing:
- China Tobacco International IPO: Heavy Regulation, Declining Margins – A Bit Late to IPO Party
- China Tobacco International (IPO): The Monopolist Will Not Recover
- RRR Rate Cut in China
- FX Reserves in China
- Healius (HLS AU): Bid Rejection Provides Option Value
1. China Tobacco International IPO: Heavy Regulation, Declining Margins – A Bit Late to IPO Party
China Tobacco International (GHALPZ CH) is a subsidiary and offshore unit of China National Tobacco Corp., a state-owned enterprise (SOE). The company procures tobacco leaves from regions around the world and exports tobacco leaf products and branded cigarettes to the duty-free outlets outside China’s customs area and in Southeast Asia.
The IPO is expected to raise US$100M and the company expects to use the proceeds to expand market share, acquire new cigarette brands, working capital, and other corporate purposes.
2. China Tobacco International (IPO): The Monopolist Will Not Recover
- China Tobacco International (HK) Co. Ltd. plans to go public on the Hong Kong Stock Exchange.
- The state-owned company holds monopolistic positions in tobacco leaf export, tobacco leaf import, and cigarette export.
- Both revenue growth and margins declined year-over-year in the first three quarters of 2018.
- We believe the China cigarette market will not recover, as all signals suggest weak demand.
3. RRR Rate Cut in China
The big news in Chinese finance was the PBOC announcing Friday that it was cutting the RRR rate. Rather than what you can read in the press, we want to focus on a variety of factors which may not be as widely recognized.
4. FX Reserves in China
FX reserves are up by about 10 billion dollars, which against a back drop of the size of FX and the Chinese economy is basically no change. They have been oddly flat over the past two years. Yet, the noise is really just that, the FX increase is so small that we believe it is a non-starter.
5. Healius (HLS AU): Bid Rejection Provides Option Value
Healius (HLS AU), formerly known as Primary Health Care (PRY AU), is a leading Australian owner of GP clinics and pathology centres. Healius just took four days to reject Jangho Group Co Ltd A (601886 CH)’s 3 January 2018 proposal of A$3.25 cash per share as it “is opportunistic and fundamentally undervalues Healius.”
We believe that rejection of Jangho’s proposal provides shareholders with option value. If Healius’ growth initiatives generate value, we believe that the shares will be worth more than Jangho’s proposal. If Healius’ growth initiatives stall and the shares slide, we believe that Jangho will once again table a proposal.
Get Straight to the Source on Smartkarma
Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.